Welcome to our dedicated page for Biophytis S.A. news (Ticker: $BPTS), a resource for investors and traders seeking the latest updates and insights on Biophytis S.A. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biophytis S.A.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biophytis S.A.'s position in the market.
Biophytis has announced the design of its Phase 2 OBA clinical study in obesity, focusing on BIO101 (20-hydroxyecdysone). The study will evaluate BIO101 in obese patients treated with GLP-1 RAs and a hypocaloric diet. CEO Stanislas Veillet highlighted the potential market for obesity treatments and the opportunity for BIO101 to preserve muscle function in these patients. The double-blind, placebo-controlled study will involve 164 patients and assess muscle strength, 6-minute walking distance, and various performance tests. The IND filing is expected soon, with the study starting mid-2024 and initial results in 2025.
Biophytis, a clinical-stage biotechnology company, is implementing a partnership strategy in obesity to develop therapeutics for age-related diseases. The company aims to find regional or global pharmaceutical partners to co-develop and commercialize BI0101 for the treatment of obesity and other indications. Biophytis is focused on driving scientific advancements to benefit obese patients worldwide and has a detailed action plan to achieve this goal.